Skip to main content

Table 1 Characteristics of targets and primary antibodies used in the study

From: In-vitro effects of the antimicrobial peptide Ala8,13,18-magainin II amide on isolated human first trimester villous trophoblast cells

Antigen Specification of antibody Final concentration Purpose*
β-actin Sheep IgGa 2.0 μg/ml Internal normalization control, used in WB
Cytokeratin 7 Mouse IgGb 6 μg/ml Epithelial cell marker, used in ICC
Cytokeratin 18 neo-epitope (CK18f) Mouse IgGc 1:50 (WB); 1:20 (ICC) Early apoptosis marker, used in WB and ICC
βhCG Rabbit IgGc 4 μg/ml (WB); 10 μg/ml (ICC) CTB differentiation marker, used in WB and ICC
hPL Goat IgGd   3 μg/ml (WB); 7 μg/ml (ICC) CTB differentiation marker, used in WB and ICC
Vimentin Mouse IgGa 3 μg/ml Cytoskeletal protein marker for fibroblasts, used in ICC
Vitronectin receptor, Integrin αVβ3 (CD51) Mouse IgGe 10 μg/ml Invasive CTB marker, used in ICC
von Willebrand factor Rabbit IgGc 25 μg/ml Endothelial cell marker (in Weibel-Palade bodies), used in ICC
  1. *see references [1719, 2327, 32] for details.
  2. CTB, cytotrophoblast cells. ICC, immunocytochemistry. WB, Western blot analysis.
  3. aR&D Systems, Minneapolis. bSigma Chemical, St Louis, MO, USA. cDako, Glostrup, Denmark. dSanta Cruz Biotechnology, Santa Cruz, CA, USA. eZymed Laboratories, San Francisco, CA, USA.